Laurent Gouya

Title: **Innovative Contributions of Laurent Gouya in Erythropoietic Protoporphyria Treatment**

Introduction

Laurent Gouya, based in Paris, France, stands out as an accomplished inventor in the field of pharmaceutical solutions for genetic disorders. With a focus on erythropoietic protoporphyria, he has made significant strides to improve treatment methodologies, earning him recognition in the scientific community.

Latest Patents

Gouya holds two notable patents related to methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria. His inventions specifically address the enhancement of functional FECH levels in erythroid cells containing the hypomorphic allele IVS3 48C/T (rs2272783). The patented methods involve introducing antisense oligonucleotides (ASO) into these cells to prevent the splicing of the cryptic exon that alters the FECH mRNA formed from the mutant IVS3 48C/T allele. This innovative approach is poised to advance therapeutic strategies for patients affected by this condition.

Career Highlights

Gouya has been associated with prominent research institutions, notably the Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Paris Diderot (Paris 7). His career reflects a deep commitment to advancing medical science, particularly in genetic research and treatment.

Collaborations

Throughout his career, Laurent Gouya has collaborated with esteemed colleagues such as Jean-Charles Deybach and Hervé Puy. These partnerships have fostered a rich exchange of knowledge and expertise, further contributing to his innovative work in the field.

Conclusion

Through his pioneering patents and collaborations, Laurent Gouya has made valuable contributions to the treatment of erythropoietic protoporphyria. With an impressive background in reputable research institutions and a dedicated focus on improving patient outcomes, Gouya exemplifies the impact that innovative inventors have on the medical field.